Advocacy group sues FDA for failing to issue warnings on Parkinson’s drugs about compulsive behaviors
STAT
By Ed Silverman
“There is clear evidence that links dopamine agonist medications to certain impulse-control problems and compulsive behaviors,” said Dr. Michael Carome, director of Public Citizen’s Health Research Group, in a statement. “The current warnings found in the product labels are far too obscure and weak and do not adequately warn prescribers and patients about these serious risks. The FDA needs to act now before these adverse effects devastate more patients’ lives.”